Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) EPS (Basic) (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed EPS (Basic) for 11 consecutive years, with -$77.78 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 39.98% year-over-year to -$77.78, compared with a TTM value of -$79.02 through Dec 2025, up 59.72%, and an annual FY2025 reading of -$79.02, up 37.88% over the prior year.
  • EPS (Basic) was -$77.78 for Q4 2025 at Spyre Therapeutics, down from -$0.15 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $51.26 in Q2 2023 and bottomed at -$480.71 in Q4 2023.
  • Average EPS (Basic) over 5 years is -$35.72, with a median of -$0.34 recorded in 2021.
  • The sharpest move saw EPS (Basic) tumbled 6851.43% in 2021, then skyrocketed 19085.19% in 2023.
  • Year by year, EPS (Basic) stood at -$24.33 in 2021, then soared by 182.9% to $20.17 in 2022, then crashed by 2483.29% to -$480.71 in 2023, then soared by 73.04% to -$129.6 in 2024, then skyrocketed by 39.98% to -$77.78 in 2025.
  • Business Quant data shows EPS (Basic) for SYRE at -$77.78 in Q4 2025, -$0.15 in Q3 2025, and $22.86 in Q2 2025.